Eposis 10000IU/ml Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 10000 IU/ml, a glycoprotein hormone that stimulates erythropoiesis by promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis, as well as anemia due to chemotherapy in cancer patients. Eposis is also utilized in reducing the need for allogeneic blood transfusions in surgical patients and in certain cases of HIV-related anemia. The administration of Eposis should be individualized based on hemoglobin levels and patient response, with careful monitoring to avoid excessive erythropoiesis and associated risks such as hypertension and thromboembolic events. Dosage adjustments are necessary in accordance with clinical response and hemoglobin targets, typically aiming to maintain hemoglobin levels sufficient to reduce transfusion requirements without exceeding recommended thresholds. Eposis is administered via subcutaneous or intravenous injection under medical supervision. Contraindications include uncontrolled hypertension and hypersensitivity to the active substance or any excipients. Caution is advised in patients with cardiovascular risk factors. Proper storage conditions and handling must be observed to maintain product stability and efficacy.